Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

brigatinib

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

- PMLiVE

FDA launches TEMPO digital health pilot

Digital technologies can improve remote patient care for those with chronic diseases

- PMLiVE

Roche’s Columvi improves survival in large B-cell lymphoma

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links